ClinicalTrials.gg
CompletedNCT00478777Updated Nov 3, 2011Results posted

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

A Phase 3 interventional study of Lenalidomide and dexamethasone in Relapsed or Refractory Multiple Myeloma, sponsored by Celgene Corporation. Completed at 48 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-03.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
51st of 249
150 · median 50
Started
2007
with 14 others
Phase 3
44 of 249
3 open now
Registered
26th of 249
by date
Lead sponsor
6 of 249
Celgene Corporation

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 51st largest by enrollment, is one of 15 that started in 2007, is one of 44 in phase 3, and was the 26th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

This was a multicenter, open-label, single-arm phase 3B study of the combination lenalidomide plus pulse high-dose dexamethasone.

This study (CC-5013-MM-019) was set up and executed primarily as an expanded access program in Germany.

Screening procedures were to take place within 28 days prior to Cycle 1 Day 1 (baseline) with the exception of hematology assessments that were to be performed within 14 days prior to Cycle 1 Day 1. Randomization, blinding, and stratification were not applied in this open-label single-arm study.

Eligible subjects given open-label treatment and received treatment with lenalidomide plus high-dose dexamethasone in 28-day cycles.

Lenalidomide (hard capsules) was to be administered orally (PO) at a dose of 25 mg daily (QD) for the first 21 days of each 28-day cycle. According to the protocol, accrual of subjects to the study was to be terminated within 2 months of commercial availability of lenalidomide for this indication in Germany.

Upon discontinuation from study, minimal information was collected in order to identify when disease progressed.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

Keywords

  • CC-5013
  • Revlimid
  • Lenalidomide
  • Celgene
  • Multiple Myeloma
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 150 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.

First submitted before Celgene became part of Bristol-Myers Squibb.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must understand and voluntarily sign an form.
  • Must be ≥18 years of age at the time of signing the informed consent form.
  • Must be able to adhere to the study visit schedule and other protocol requirements.
  • Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles of anti-myeloma treatment or that has with progressive disease after treatment.
  • Subjects may have been previously treated with thalidomide and/or radiation therapy. In addition, radiation therapy initiated prior to or at baseline (Day 1) may be given concurrently with study therapy, provided that all other eligibility criteria are satisfied.
  • Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the first dose of study drug with the exception of radiation therapy initiated prior to or at baseline (Day 1).
  • Measurable levels of myeloma paraprotein in serum (>0.5 g/dL) or urine (>0.2 g excreted in a 24-hour collection sample).
  • (ECOG) performance status score of 0, 1, or 2.
  • Females of (FCBP) must agree to use two reliable forms of simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study.

Exclusion criteria

Exclusion Criteria:

  • The presence of any of the following will exclude a subject from study enrollment:
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form.
  • Pregnant or lactating females.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Any of the following laboratory abnormalities:

    • (ANC) \<1,000 cells/mm\^3 (1.0 x 10\^9/L)
    • count \<75,000/mm\^3 (75 x 109/L) for subjects in whom \<50% of the bone marrow nucleated cells are plasma cells.
    • Platelet count \<30,000/mm\^3 (30x10\^9/L) for subjects in whom ≥50% of bone marrow nucleated cells are plasma cells.
    • Serum creatinine >2.5 mg/dL (221 µmol/L)
    • Serum /AST or SGPT/ALT >3.0 x (ULN)
    • Serum total >2.0 mg/dL (34 µmol/L)
  • Prior history of other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥1 year.
  • Prior history of stroke and/or thromboembolic event
  • Known to thalidomide or dexamethasone.
  • Prior history of uncontrollable side effects to dexamethasone therapy.
  • The development of a desquamating rash while taking thalidomide.
  • Neuropathy ≥ Grade 2.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    lenalidomide plus dexamethasone

    Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.

    Drug: Lenalidomide · Drug: dexamethasone

Interventions

  • Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.

    Also known as: Revlimid®

  • Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.

07

What researchers measure

Primary outcomes

  1. Kaplan Meier Estimate for Time to Disease Progression

    Time to disease progression (TTP) was based on the European Group for Blood and Marrow Transplantation (EBMT) myeloma response determination criteria developed by Bladé (Bladé, 1998). TTP is a Kaplan Meier estimate of the time from randomization to the first documentation of progressive disease. Progressive disease based on increasing monoclonal paraprotein levels require a confirmatory value one week apart. Disease progression can also be based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

    Time frame: up to 827 days

Secondary outcomes

  1. Participant's Best Overall Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Criteria

    Best overall response was calculated as the best assessment from all cycles (including treatment discontinuation visit) and follow-up. The response rate was summarized as complete response (CR), partial response (PR), stable disease (SD), progression (PD), response not evaluable, and derived categories (PR+CR) and (PR+CR+SD). CR is negative immunofixation on both serum and urine maintained for 6 weeks straight. PR is a 50% decrease in serum paraprotein maintained for 6 weeks straight. SD is serum paraprotein values within 25% of baseline.

    Time frame: Up to 827 days

  2. Participants With Treatment-emergent Adverse Experiences (TEAEs)

    Counts of study participants who had treatment-emergent adverse events (TEAEs) defined as any reported AE that started on or after the first day of study drug dosing. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) was used by investigators to assess TEAEs. Severity scale ranges from 0 (none) to 5 (death). Grade 3=severe AE; Grade 4=life threatening or disabling AE; Grade 5=death.

    Time frame: up to 8 months

  3. Time to Partial Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Determination Criteria

    Time to partial response is the time from randomization to a 50% decrease in serum paraprotein maintained for six weeks straight. This was determined by free light chain concentrations which were taken every two weeks during the treatment phase of the trial.

    Time frame: up to 827 days

08

Results

Posted Nov 3, 2011

Participant flow

A total of 150 participants in 37 sites in Germany were enrolled when lenalidomide became commercially available in Germany. Study completion (end of study) was the time point when participants discontinued study drug and could switch to commercial lenalidomide.

Participant flow — Overall Study
MilestoneLenalidomide Plus Dexamethasone
Started150
Safety and full analysis set (fas)144
Completed73
Not completed77
Withdrew: Adverse event29
Withdrew: Lack of efficacy23
Withdrew: Withdrawal by subject4
Withdrew: Death3
Withdrew: Protocol violation3
Withdrew: Lost to follow-up3
Withdrew: Physician decision1
Withdrew: Intolerance of therapy1
Withdrew: Lack of compliance1
Withdrew: Lymphocytes infusion1
Withdrew: End of therapy2
Withdrew: Not treated with lenalidomide6

Outcome measures

PrimaryKaplan Meier Estimate for Time to Disease Progression

Time to disease progression (TTP) was based on the European Group for Blood and Marrow Transplantation (EBMT) myeloma response determination criteria developed by Bladé (Bladé, 1998). TTP is a Kaplan Meier estimate of the time from randomization to the first documentation of progressive disease. Progressive disease based on increasing monoclonal paraprotein levels require a confirmatory value one week apart. Disease progression can also be based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Time frame:
up to 827 days
Reported as:
Median · days
Kaplan Meier Estimate for Time to Disease Progression
daysLenalidomide Plus Dexamethasone
Kaplan Meier Estimate for Time to Disease Progression214.0 (146 to 281)
SecondaryParticipant's Best Overall Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Criteria

Best overall response was calculated as the best assessment from all cycles (including treatment discontinuation visit) and follow-up. The response rate was summarized as complete response (CR), partial response (PR), stable disease (SD), progression (PD), response not evaluable, and derived categories (PR+CR) and (PR+CR+SD). CR is negative immunofixation on both serum and urine maintained for 6 weeks straight. PR is a 50% decrease in serum paraprotein maintained for 6 weeks straight. SD is serum paraprotein values within 25% of baseline.

Time frame:
Up to 827 days
Reported as:
Number · participants
Participant's Best Overall Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Criteria
participantsLenalidomide Plus Dexamethasone
Complete response (CR)6
Partial response (PR)97
Stable disease (SD)30
Progressive disease (PD)3
Not evaluable (NE)8
CR + PR103
CR + PR + SD133
SecondaryParticipants With Treatment-emergent Adverse Experiences (TEAEs)

Counts of study participants who had treatment-emergent adverse events (TEAEs) defined as any reported AE that started on or after the first day of study drug dosing. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) was used by investigators to assess TEAEs. Severity scale ranges from 0 (none) to 5 (death). Grade 3=severe AE; Grade 4=life threatening or disabling AE; Grade 5=death.

Time frame:
up to 8 months
Reported as:
Number · participants
Participants With Treatment-emergent Adverse Experiences (TEAEs)
participantsLenalidomide Plus Dexamethasone
>=1 TEAE139
>=1 TEAE related to study drug119
>=1 NCI CTCAE grade 3 or 4 TEAE105
>=1 NCI CTCAE grade 3 or 4 TEAE related to drug83
>=1 serious AE (SAE)79
>=1 study drug related SAE48
Discontinued due to TEAE32
Discontinued due to TEAE related to study drug21
TEAE leading to dose reduction35
TEAE leading to dose interruption64
Deaths79
SecondaryTime to Partial Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Determination Criteria

Time to partial response is the time from randomization to a 50% decrease in serum paraprotein maintained for six weeks straight. This was determined by free light chain concentrations which were taken every two weeks during the treatment phase of the trial.

Time frame:
up to 827 days
Reported as:
Mean · Days

No measurements were reported for this outcome.

Adverse events

Collected over Up to 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide Plus Dexamethasone—79/144 (54.9%)129/144 (89.6%)
Most frequent serious events
Showing 10 of 111
Most frequent serious events
EventLenalidomide Plus Dexamethasone
PyrexiaGeneral disorders14/144
PneumoniaInfections and infestations8/144
General physical health deteriorationGeneral disorders6/144
SepsisInfections and infestations6/144
Multiple myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/144
DiarrhoeaGastrointestinal disorders5/144
AnaemiaBlood and lymphatic system disorders5/144
NeutropeniaBlood and lymphatic system disorders4/144
Renal failureRenal and urinary disorders4/144
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/144
Most frequent other events
Showing 10 of 29
Most frequent other events
EventLenalidomide Plus Dexamethasone
Muscle spasmsMusculoskeletal and connective tissue disorders35/144
FatigueGeneral disorders33/144
LeukopeniaBlood and lymphatic system disorders28/144
ThromboyctopeniaBlood and lymphatic system disorders25/144
DiarrhoeaGastrointestinal disorders22/144
ConstipationGastrointestinal disorders20/144
Oedema peripheralGeneral disorders19/144
PyrexiaGeneral disorders18/144
DizzinessNervous system disorders17/144
TremorNervous system disorders15/144

Baseline characteristics

Age Continuous
Age Continuous(years)Lenalidomide Plus Dexamethasone
Mean64.7 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide Plus Dexamethasone
Female68
Male76
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lenalidomide Plus Dexamethasone
White142
Other2
Region of Enrollment
Region of Enrollment(participants)Lenalidomide Plus Dexamethasone
Germany144
09

Study locations

48 sites
  • Medizinische Klinik und Poliklinik II der Charité Universitätsmedizin Berlin Campus Mitte
    Berlin, 10117, Germany
  • Poliklinik I, Hämatologie/ Onkologie, Universitätsklinikum Bonn
    Bonn, 53105, Germany
  • Johanniter-Krankenhaus Bonn Friedrich-Wilhelm-Stift gGmbH
    Bonn, 53113, Germany
  • Medizinische Klinik Städtisches Klinikum Braunschweig gGmbH
    Braunschweig, D-38114, Germany
  • Interne Klinik Dr. Argirov, Schön-Kliniken
    Burg, 82335, Germany
  • Klinik für Innere Medizin III Klinikum Chemnitz gGmbH
    Chemnitz, 09113, Germany
  • Medizinische Klinik und Poliklinik, Uniklinikum Dresden
    Dresden, 01307, Germany
  • Universitaetsklinikum Dusseldorf Klinik fuer Haematologie
    Düsseldorf, 40225, Germany
  • Direktor der Klinik f. Hämatologie, Universitätsklinikum Essen
    Essen, 45122, Germany
  • Universitätsklinikum EssenInnere Klinik und Poliklinik
    Essen, 45122, Germany
  • Klinik für Innere Medizin, Klinikum Frankfurt (Oder) GmbH
    Frankfurt (Oder), 15236, Germany
  • Medizinische Klinik II (ZIM),Hämatologie / Onkologie Uniklinik Frankfurt
    Frankfurt am Main, 60590, Germany
  • Abt. Innere Medizin I , Hämatologie / Onkologie, Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • Universitätsklinikum GöttingenHamatologie und Onkologie
    Göttingen, 37075, Germany
  • Interdisziplinäre Klinik und Poliklinik für Stammzellentransplantation Universitätsklinik Hamburg - Eppendorf
    Hamburg, 20246, Germany
  • II. Medizinische Abteilung, Asklepios Klinikum Altona
    Hamburg, 22763, Germany
  • Abt. Hämatologie, Hämatologie und Onkologie, Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Medizinische Klinik und Poliklinik V Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Klinik für Innere Medizin II Hämatologie / Onkologie Universitätsklinikum Jena
    Jena, 07740, Germany
  • EPS - Early Phase Solutions GmbH
    Jena, 07743, Germany
  • Hämatologie / Onkologie / Infektionskrankheiten, Palliativmedizin Städtisches Klinikum Karlsruhe
    Karlsruhe, 76135, Germany
  • 2. Med. Klinik , Sektion f. Stammzell- + Immuntherapie Universitätsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Institut für Versorgungsforschung in der Onkologie Praxisklinik für Hämatologie und Onkologie
    Koblenz, 56068, Germany
  • Ärzte f. Innere Medizin Gemeinschaftspraxis f. Hämatologie u. Onkologie
    Köln, 50677, Germany
  • Klinik f. Innere Medizin, Klinikum der Universität zu Köln
    Köln, 50924, Germany
  • Medizinische Klinik und Poliklinik II Abt. Hämatologie / Onkologie, Universitätsklinikum Leipzig AÖR
    Leipzig, 04103, Germany
  • III. Med. Klinik, Johannes Gutenberg Universität
    Mainz, 55101, Germany
  • Klinikum Mannheim der Universität Heidelberg
    Mannheim, 68305, Germany
  • Hämatologisch-Onkologisches Institut für medizinische Service Leistungen
    Mönchengladbach, 41239, Germany
  • Medizinische Klinik III Klinikum der Universität München-Großhadern
    München, 81377, Germany
  • Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster
    Münster, 48129, Germany
  • Fachärzte für Innere Medizin Hämatologie und Onkologie Gemeinschaftspraxis
    Münster, 48149, Germany
  • Onkologie Praxis Oldenburg
    Oldenburg, 26121, Germany
  • Abt. Onkologie/ Hämatologie, Klinikum Oldenburg
    Oldenburg, 26133, Germany
  • Abteilung Hämatologie und Onkologie, Hämatologie und Onkologie, Medizinische Klinik, Klinikum Ernst v. Bergmann
    Potsdam, 14467, Germany
  • Klinikum der Universität Regensburg
    Regensburg, 93053, Germany
  • Abteilung Hämatologie und Onkologie, Medizinische Fakultät der Universität Rostock
    Rostock, 18057, Germany
  • Caritasklinik St. Theresia
    Saarbrucken, 66113, Germany
  • ms² Medizinische Statistik Saarbrücken
    Saarbrucken, D-66113, Germany
  • Med. Klinik III , St. Marienkrankenhaus Siegen
    Siegen, 57072, Germany
  • Zentrum für Innere Medizin II Robert- Bosch-Krankenhaus GmBH
    Stuttgart, D -70376, Germany
  • Krankenanstalt Mutterhaus der Borromäerinnen
    Trier, 54290, Germany
  • Abt. II Hämatologie, Onkologie und Immunologie Medizinische Klinik Abt.II
    Tübingen, 72076, Germany
  • Medizinische Universitätsklinik
    Ulm, 89081, Germany
  • Praxis Dres. Maintz & GroschekHämatologie / Onkologie
    Wuerselen, 52146, Germany
  • Med. Klinik 1, Helios Klinikum Wuppertal
    Wuppertal, 42283, Germany
  • Med. Klinik u. Poliklinik IIKlinikum der Universität Würzburg
    Würzburg, 97080, Germany
  • Hämatologisch-onkologische Praxis
    Würzburg, D-97070, Germany
10

References and documents

Publications

  • Weisel, Katja Christina, et. al. Speed of Response with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: First Results of the MM-019 Compassionate Use Protocol. 14th Congress of the European Hematology Association, June 2009. Haematologica 2009; 94(Suppl 2):160 abs.0397. http://www.eventure-online.com/eventure/publicAbstractView.do?id=101710&congressId=2432
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Nov 2007 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2007
First posted
May 25, 2007
Start
Mar 2007
Primary completionActual
Nov 2007
CompletionActual
Aug 2009
Results first posted
Nov 3, 2011
Last update
Nov 3, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00478777
Responsible party
Sponsor
First posted
May 25, 2007
Start date
Mar 2007
Primary completion
Nov 2007
Completion
Aug 2009
Results posted
Nov 3, 2011
Last update
Nov 3, 2011

Study contacts

Axel Glasmacher, MD
principal investigator · University of Bonn

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Dexamethasone

Start the discussion